LS Investment Advisors LLC Has $1.60 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

LS Investment Advisors LLC decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,582 shares of the medical research company’s stock after selling 100 shares during the period. LS Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,597,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of TMO. CFO4Life Group LLC bought a new position in shares of Thermo Fisher Scientific in the first quarter valued at approximately $234,000. Empowered Funds LLC grew its stake in Thermo Fisher Scientific by 53.3% in the 1st quarter. Empowered Funds LLC now owns 7,704 shares of the medical research company’s stock valued at $4,478,000 after purchasing an additional 2,677 shares during the period. Hilltop National Bank bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth $487,000. Nelson Capital Management LLC grew its position in Thermo Fisher Scientific by 3.7% during the first quarter. Nelson Capital Management LLC now owns 8,422 shares of the medical research company’s stock valued at $4,895,000 after buying an additional 298 shares during the period. Finally, Forsta AP Fonden increased its holdings in Thermo Fisher Scientific by 10.5% during the first quarter. Forsta AP Fonden now owns 92,770 shares of the medical research company’s stock worth $53,919,000 after buying an additional 8,800 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on TMO shares. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Sanford C. Bernstein lowered their target price on Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating on the stock in a research note on Thursday, October 24th. Redburn Atlantic started coverage on shares of Thermo Fisher Scientific in a report on Monday, October 14th. They set a “buy” rating and a $680.00 price objective on the stock. Bernstein Bank raised their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a report on Tuesday, October 22nd. Finally, Stifel Nicolaus dropped their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $649.33.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $555.89 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $437.26 and a 1-year high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The business has a 50 day moving average of $596.33 and a 200 day moving average of $583.80. The company has a market capitalization of $212.63 billion, a price-to-earnings ratio of 34.85, a PEG ratio of 3.70 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. During the same quarter last year, the company earned $5.69 EPS. The firm’s revenue was up .2% compared to the same quarter last year. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s payout ratio is currently 9.78%.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at $67,175,513.68. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the transaction, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the sale, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,175,513.68. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,150 shares of company stock worth $10,094,925. Insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.